Trial Profile

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pyrotinib (Primary) ; Antineoplastics; Capecitabine; Trastuzumab
Indications Advanced breast cancer; HER2 positive breast cancer
Focus Therapeutic Use

Most Recent Events

08 Jun 2021 Results (N=132) of an analysis assessing the efficacy and safety of pyrotinib in patents with histologically confirmed advanced HER2 positive breast cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology
11 Dec 2020 Results (n=231) presented at the 43rd Annual San Antonio Breast Cancer Symposium
21 Jan 2020 Status changed from not yet recruiting to recruiting as per Results presented at the 42nd Annual San Antonio Breast Cancer Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com